SARS-CoV-2 and cancer

1562MO - Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study

Julie T. Wu, et al.


Vaccination is an effective strategy for preventing COVID-19 in cancer patients. However, effectiveness may be reduced in patients actively receiving immunosuppressive systemic therapy. Future study is needed to determine if these patients would benefit from post-vaccination serologies and/or a booster vaccination following completion of therapy.


1563MO - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

Radka Obermannova, et al.


Substantial number of cancer patients experienced SARS-CoV-2 infection during active anti-cancer treatment prior to vaccination, often with asymptomatic course. In SARS-CoV-2-immunized patients, we observed SARS-CoV-2 positive cellular response. The preliminary results with dynamics of immune response with 3-month follow-up will be presented at the conference. Acknowledgment: CZECRIN LM2018128, Roche Diagnostics, MMCI00209805, MHCZ/DRO (FNBr, 65269705).


1564MO - Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers

Sabrina K. Salgia, et al.


Our data prompt concern for delayed or insufficient COVID-19 Ab response in a subset of pts with advanced GU cancers.


LBA60 - Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK

Tom Drake, et al.


Europe’s largest prospective hospitalised COVID-19 dataset continues to demonstrate that cancer is independently associated with mortality with younger patients remaining at increased relative risk. Cancer patients face unique risks from the SARS-CoV- 2 pandemic. Ongoing vaccination/mitigation studies need to recruit cancer patients to understand the degree of protection afforded in this at risk population.


1565MO - Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry

David J. Pinato, et al.


We report a time-dependent improvement in the mortality from COVID-19 in European cancer patients. This may be explained by expanding testing capacity, improved healthcare resources and dynamic changes in community transmission over time. These findings are informative for clinical practice and policy making in the context of an unresolved pandemic.


1566MO - Resilience of elective cancer surgery systems during COVID-19 lockdowns: International, prospective cohort study of planned surgery for 15 tumour types in 61 countries

James Glasbey, et al.


Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients not undergoing planned surgery and more preoperative delays. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which may include ring-fenced surgical units and critical care capacity.


1567MO - COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)

Emanuela Romano, et al.


Demographic characteristics, type and status of cancer, and symptomatology of COVID-19 increase the probability of severe disease, while advanced cancer stage is also associated with the risk of death.